FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Edscharp who wrote (23)	10/7/1999 8:55:00 PM
From: opalapril	Read Replies (2) of 75

I saw that. It seems to me there are only four ways to invest wisely (not gamble) in biotechs without a marketable product, given the FDA and the market atmosphere we've had for some years, now. (1) Wait out promising drugs through all the trials and then buy as fast as you can when FDA approval is awarded or seems assured (a strategy that worked very well for everybody watching PFE bringing Viagra to the FDA); 2) Trade in moderation, or in other words identify the pattern and the price range of a given biotech which is a long way from FDA approval, then buy at the lows and sell at the highs until approval time draws very near; (3) Buy solid companies with long-term prospects after they suffer some unexpected or unwarranted hit owing to a non-fundamental, short-term problem; and (4) live lucky. If, as you say, Imclone was wrongfully beaten up, I'd say you were living lucky. I don't follow the company or know its patent position, but isn't it fairly standard for a company accused of infringement to issue public denial statements? Sort of like, "I am not a crook." (Nixon, 1973) or "I was in Chicago cutting my hand with a glass."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next